Merck has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for KEYTRUDA, in combination with Padcev, as perioperative treatment for adults with cisplatin-ineligible resectable muscle-invasive bladder cancer. The recommendation covers use before radical cystectomy as neoadjuvant treatment and continued after surgery as adjuvant treatment, placing the regimen closer to a European Commission decision expected by the third quarter of 2026.

The significance is not limited to another regulatory step for a major oncology franchise. If cleared in Europe, KEYTRUDA plus Padcev would become the first PD-1 inhibitor and antibody-drug conjugate combination approved for this specific perioperative bladder cancer population, potentially changing how clinicians approach patients who cannot receive cisplatin-based chemotherapy.

Why the CHMP opinion could matter more than a routine label expansion for Merck

The positive CHMP opinion comes at a strategically important point for Merck’s oncology business because it moves KEYTRUDA deeper into earlier-stage disease, where treatment intent is more often curative and where clinical endpoints can influence long-term standards of care. For years, KEYTRUDA has been central to Merck’s leadership in immuno-oncology, but the next phase of competition is increasingly about how immune checkpoint inhibitors perform before or after surgery, not only in metastatic disease.

For muscle-invasive bladder cancer, that shift is especially relevant. The traditional backbone for eligible patients has been cisplatin-based chemotherapy before surgery, followed by radical cystectomy. The problem is that a large share of patients cannot receive cisplatin because of renal function, hearing loss, neuropathy, frailty, performance status, or other clinical factors. That leaves a major treatment gap in a disease where recurrence risk after surgery remains substantial.

KEYTRUDA plus Padcev directly targets that gap. The regimen combines pembrolizumab, a PD-1 inhibitor designed to help restore anti-tumour immune activity, with enfortumab vedotin, an antibody-drug conjugate directed at Nectin-4. The rationale is commercially attractive and clinically ambitious because it pairs immune activation with targeted cytotoxic delivery. However, the same ambition also raises adoption questions, particularly around toxicity management, patient selection, and how easily multidisciplinary cancer centres can incorporate the regimen before and after surgery.

What KEYNOTE-905 reveals about the changing treatment logic in bladder cancer

The CHMP recommendation rests on the Phase 3 KEYNOTE-905 trial, also known as EV-303, which evaluated KEYTRUDA plus Padcev as perioperative treatment against surgery alone in patients with muscle-invasive bladder cancer who were ineligible for or declined cisplatin-based chemotherapy. The trial reported statistically significant improvements across event-free survival, overall survival, and pathologic complete response rate, making the dataset more persuasive than a single-endpoint readout.

The headline efficacy figures are difficult to ignore. The combination reduced the risk of event-free survival events by 60%, with a hazard ratio of 0.40. It also reduced the risk of death by 50%, with a hazard ratio of 0.50. The pathologic complete response rate reached 57.1% with KEYTRUDA plus Padcev, compared with 8.6% for surgery alone. In practical terms, the data suggest that treatment before surgery may be doing more than shrinking tumours on paper. It may be changing the biological course of disease for a patient group that has historically had fewer effective systemic options.

That said, the comparator matters. Surgery alone is a clinically relevant option for cisplatin-ineligible patients, but it is not the same as defeating an active perioperative systemic regimen. Regulatory reviewers and clinicians may view the results as highly meaningful for the intended population, while still asking how the regimen will compare with emerging alternatives, real-world treatment patterns, and future perioperative combinations. The data raise the ceiling for what can be expected in cisplatin-ineligible disease, but they do not end the broader debate over optimal sequencing.

How the regimen could change perioperative decision-making before radical cystectomy

The most immediate clinical shift would be the expansion of meaningful pre-surgical treatment options for patients previously routed toward surgery alone. For urologic oncologists and medical oncologists, that could change the timing and intensity of conversations at diagnosis. Instead of treating cisplatin ineligibility as a narrowing of options, care teams may begin discussing a perioperative immunotherapy and antibody-drug conjugate strategy earlier in the pathway.

This is important because muscle-invasive bladder cancer is not managed by one specialty in isolation. Treatment often requires coordination between urology, medical oncology, radiology, pathology, anaesthesia, and perioperative care teams. A neoadjuvant plus adjuvant regimen adds complexity because patients must be assessed not only for cancer biology, but also for surgical readiness, treatment tolerance, and timing. A strong efficacy signal can support adoption, but operational coordination will determine how consistently the regimen reaches eligible patients.

The unresolved issue is whether real-world patients will resemble trial participants closely enough to reproduce the same benefit-risk profile. Cisplatin-ineligible bladder cancer patients are often older and medically complex. KEYNOTE-905 reported notable adverse reactions in the combination arm, including rash, pruritus, fatigue, peripheral neuropathy, diarrhoea, urinary tract infection, and weight loss. Clinicians may welcome the efficacy data while still moving cautiously in frailer patients, particularly those at higher risk of treatment-related complications before major surgery.

Why safety and surgical timing will remain central to uptake in Europe

The key adoption question is not whether the efficacy data are strong. It is whether the regimen can be delivered safely and predictably around radical cystectomy. In the neoadjuvant phase of KEYNOTE-905, serious adverse reactions occurred in 27% of cisplatin-ineligible patients treated with the combination. Some patients did not proceed to surgery due to adverse reactions, and a smaller share experienced surgery delays after neoadjuvant treatment.

That does not negate the benefit shown in the trial, but it highlights why implementation will require discipline. Perioperative cancer therapy carries a different risk calculation from metastatic treatment because any delay or cancellation of surgery can have significant consequences. A regimen that improves event-free and overall survival must still fit into surgical timelines without creating unacceptable perioperative risk.

European adoption may also vary by country because reimbursement systems, bladder cancer pathways, surgical capacity, and oncology infrastructure differ across markets. Large academic centres may adopt the regimen faster, especially where multidisciplinary uro-oncology pathways are mature. Smaller centres may need clearer protocols for toxicity monitoring, referral timing, and post-surgical continuation. The commercial opportunity is meaningful, but it will be shaped by how easily health systems can standardise delivery.

What the recommendation means for Merck, Pfizer, and Astellas in antibody-drug conjugate oncology

The CHMP opinion also reinforces the growing importance of antibody-drug conjugates in mainstream oncology strategy. Padcev, developed through the Pfizer and Astellas alliance, has already reshaped expectations in advanced urothelial cancer when combined with KEYTRUDA. Moving the combination into earlier disease would extend that logic into a more treatment-sensitive setting, where durable outcomes carry greater clinical and commercial value.

For Merck, the positive opinion strengthens the argument that KEYTRUDA remains a platform asset rather than a single-product franchise nearing maturity. For Pfizer and Astellas, the development further validates Padcev as a combination partner beyond metastatic disease. The broader industry message is that ADCs are no longer just later-line targeted therapies. They are increasingly being tested as foundational partners in earlier and potentially curative treatment settings.

The risk is that success raises expectations for cleaner, more durable, and more scalable ADC combinations. Antibody-drug conjugates can deliver strong activity, but toxicity profiles can be complex, particularly when paired with immunotherapy. Peripheral neuropathy, skin reactions, ocular effects, fatigue, and infection-related complications are not trivial in older bladder cancer populations. Competitors will likely study whether other ADCs, checkpoint inhibitors, or biomarker-led approaches can deliver comparable outcomes with different tolerability trade-offs.

Why the European Commission decision will be watched beyond bladder cancer specialists

The European Commission usually follows CHMP recommendations, although formal authorisation is still required before the regimen can be marketed for this indication across the European Union, Iceland, Liechtenstein, and Norway. The expected third-quarter 2026 decision will therefore be watched by oncology developers, payers, and clinical guideline groups as much as by bladder cancer specialists.

A positive decision would align Europe more closely with the United States, where KEYTRUDA and the subcutaneous pembrolizumab formulation in combination with Padcev were approved in November 2025 for neoadjuvant treatment and continued adjuvant treatment after cystectomy in cisplatin-ineligible muscle-invasive bladder cancer. That transatlantic regulatory alignment matters because it can accelerate guideline discussions, strengthen physician familiarity, and support broader confidence in the perioperative strategy.

However, reimbursement will be the real-world test after approval. European payers will likely examine the magnitude of survival benefit, the cost of combination therapy, the duration of neoadjuvant and adjuvant treatment, adverse event management costs, and the potential to reduce recurrence-related downstream spending. The regimen has a strong clinical case, but health technology assessment bodies will still demand evidence that the benefit justifies the budget impact.

What clinicians and industry observers are likely to watch after approval

The next phase will likely focus on three practical questions. The first is whether clinicians can identify the patients most likely to benefit from KEYTRUDA plus Padcev without exposing lower-risk patients to unnecessary toxicity. The second is whether treatment can be integrated smoothly into cystectomy pathways without creating avoidable delays. The third is whether longer-term follow-up confirms durable survival gains across subgroups, especially older patients and those with multiple comorbidities.

There will also be interest in the role of KEYTRUDA SC, known as KEYTRUDA QLEX in the United States, because subcutaneous administration could affect convenience and infusion capacity if incorporated into European practice. Shorter administration times may matter for stretched oncology systems, but convenience alone will not drive adoption unless efficacy, safety, reimbursement, and pathway integration remain compelling.

For Merck, the CHMP opinion adds another layer to a broader strategy of moving KEYTRUDA into earlier treatment settings across tumour types. For Pfizer and Astellas, it strengthens Padcev’s position in urothelial cancer and reinforces the strategic value of ADC combinations. For patients who cannot receive cisplatin, the development is more direct. It may open the door to a systemic treatment approach where surgery alone has too often been the default.

The central story is therefore not just a European regulatory milestone. It is a sign that bladder cancer treatment is being reorganised around perioperative intensification, combination biology, and the search for better outcomes in patients historically left with limited options. The promise is substantial. The next test is whether European oncology systems can turn that promise into consistent, safe, and reimbursed clinical practice.

  antibody-drug conjugates, Astellas, bladder cancer, CHMP, enfortumab vedotin, European Commission, European Medicines Agency, EV-303, KEYNOTE-905, Keytruda, Merck, muscle-invasive bladder cancer, oncology, PADCEV, pembrolizumab, Pfizer, urothelial cancer